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In the present study, we demonstrate that ectopic expression of 
56-kDa human selenium binding protein-1 (hSP56) in PC-3 
cells that do not normally express hSP56 results in a marked 
inhibition of cell growth in vitro and in vivo. Down-regulation 
of hSP56 in LNCaP cells that normally express hSP56 results in 
enhanced anchorage-independent growth. PC-3 cells 
expressing hSP56 exhibit a significant reduction of hypoxia 
inducible protein (HIF)-1α protein levels under hypoxic 
conditions without altering HIF-1α mRNA (HIF1A) levels. 
Taken together, our findings strongly suggest that hSP56 plays a 
critical role in prostate cells by mechanisms including negative 
regulation of HIF-1α, thus identifying hSP56 as a candidate 
anti-oncogene product. [BMB Reports 2014; 47(7): 411-416]
INTRODUCTION
The 56-kDa human selenium binding protein-1 (hSP56) is ex-
pressed widely in normal cells and tissues (1-3). Interestingly, 
hSP56 expression is reduced markedly in several primary can-
cers and cancer cell lines compared to their normal counter-
parts (1, 4-13). Reduced hSP56 expression also has been corre-
lated with poor outcome in several cancers (4, 6, 10, 11), im-
plicating hSP56 in the modulation of both the incidence and 
the aggressiveness of cancer. However, this association has not 
been studied at the molecular level and it is unknown if re-
duced hSP56 expression itself results in a more malignant 
phenotype. We have investigated the effect of hSP56 ex-
pression on cancer cell growth properties using two well-stud-
ied human prostate cancer cell lines, LNCaP and PC-3. 
Relatively high levels of hSP56 are expressed in LNCaP cells, 
while little-to-no expression of hSP56 is detected in PC-3 cells 
at either the mRNA or protein levels (1, 14). We show that 
hSP56 influences the cell growth and phenotype significantly 
both in vitro and in vivo.
　We also show that PC-3 cells expressing hSP56 exhibit a sig-
nificant reduction of HIF-1α protein levels under hypoxic con-
ditions without altering HIF-1α mRNA (HIF1A) levels. HIF-1α 
is a key transcription factor for the cellular response to oxygen 
availability (15-17). HIF-1α is rapidly degraded under nor-
moxic conditions through the interactions of its hydroxylated 
proline residues with pVHL, a component of an E3 ubiquitin 
ligase complex that mediates ubiquitination-dependent protein 
degradation of target proteins (16). Under hypoxic conditions, 
HIF-1α is not hydroxylated, resulting in its protection from the 
pVHL-mediated protein degradation. The stabilized HIF-1α is 
translocated into the nucleus where it activates a number of 
genes, including those important for cell proliferation, angio-
genesis, glycolysis and erythropoiesis (17) by binding to hypo-
xia response elements (HREs). Much has been learned about 
HIF-1α in recent years, but more detailed mechanisms and fac-
tors involved in HIF-1α regulation remain to be understood. 
Our findings suggest that hSP56 plays an important role in reg-
ulating HIF-1α, which may be one of mechanisms of hSP56 
expression in suppressing the malignant characteristics of pros-
tate cancer cells. 
RESULTS AND DISCUSSION
hSP56 suppresses malignant characteristics of prostate cancer 
cells
We established PC-3 cells stably expressing hSP56 (PC-3/ 
hSP56) and LNCaP cells with hSP56 stably knocked down 
(LNCaP/hSP56
KD) to be used in this study (Fig. 1A). PC-3 cells 
or PC-3 cells stably transfected with vector (PC-3/V) did not ex-
hibit detectable hSP56 expression (1, 14). PC-3/hSP56C1 (clone hSP56 modulates the prostate cancer phenotype
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Fig. 1. hSP56 expression exhibited profound effects on prostate 
cancer cell growth. (A) Establishment of stable cell lines, 
PC-3/hSP56 and LNCaP/hSP56
KD cells. (B, C) Cell growth curves 
of PC-3 cells and derivatives (B), or LNCaP cells and derivatives 
(C) in anchorage-dependent liquid cultures. (D) Soft agar col-
ony-forming assay. Number of colonies and their size were ana-
lyzed using the ImageJ software (NIH). Similar results were ob-
tained in repeated experiments. Scale bar, 500 μm. (E) In vivo tu-
morigenicity experiment. (F) Pictures of representative mice taken 
at week 9. The site of injection is marked with dotted circle in 
one of the pictures.
1) expressed hSP56 at levels similar to LNCaP cells, while 
PC-3/hSP56C6 expressed approximately 10% of hSP56 com-
pared to that of LNCaP cells. LNCaP/hSP56
KDF10 cells ex-
hibited undetectable hSP56 expression compared to LNCaP 
cells or LNCaP cells stably transfected with another shRNA 
construct designed for hSP56, which failed to down regulate 
hSP56 expression (designated LNCaP/C). 
　PC-3/hSP56 grew much slower than PC-3 or PC-3/V cells in 
anchorage-dependent liquid culture in a manner dependent on 
hSP56 expression level (Fig. 1B). The higher the hSP56 ex-
pression level is, the slower the growth becomes, as repre-
sented by PC-3/hSP56C1. PC-3/hSP56C6 exhibited an inter-
mediate growth rate between PC-3/V and PC-3/hSP56C1. The 
slower growth rate of PC-3/hSP56C1 or C6 was not observed 
at earlier passages after transfection during the clonal selection 
procedures, therefore implying that hSP56 expression has a 
long-term effect on cell growth regulation rather than immedi-
ate effect. The clones with high levels of hSP56 expression in-
cluding PC-3/hSP56C1 either stopped growing in later pas-
sages or gradually lost hSP56 expression (Supplementary Fig. 
S1), suggesting that high expression levels of hSP56 may have 
a pronounced inhibitory action on cell growth. Therefore, we 
continued our experiments using PC-3/hSP56C6 or using fresh-
ly prepared cells with hSP56 expression levels similar to 
PC-3/hSP56C6 and comprehensively designated as PC-3/ 
hSP56. While PC-3/hSP56 cells exhibited remarkable differ-
ences in cell growth properties, LNCaP/hSP56
KD F10 or an ad-
ditional clone A7, expressing also undetectable hSP56, did not 
appear to have alterations in growth properties in anchor-
age-dependent liquid culture (Fig. 1C).
　hSP56 expression in PC-3 cells had a profound inhibitory ef-
fect on anchorage-independent cell growth in soft agar as well 
(Fig. 1D). PC-3/V cells exhibited robust growth in soft agar, 
producing 160 colonies per microscopic field with an average 
size of 3,575 μm
2. In marked contrast, PC-3/hSP56 cells ex-
hibited significantly reduced anchorage-independent growth, 
producing 136 colonies with an average size of 1,509 μm
2. 
Importantly, in the reciprocal (hSP56 knockdown) experiment, 
LNCaP/hSP56
KDF10 cells exhibited significantly enhanced col-
ony formation (49 colonies with an average size of 606 μm
2) 
compared to the virtual absence of colonies formed by 
LNCaP/C cells (15 colonies, 171 μm
2) (additional microscopic 
fields are provided in Supplementary Fig. S2). To test the effect 
of hSP56 expression on tumorigenicity in vivo, we trans-
planted PC-3/V cells or PC-3/hSP56 cells subcutaneously into 
groups of eight male SCID mice. Starting one month after in-
jection, tumor size was measured weekly and tumor volume 
was calculated. The growth rate of the PC-3/hSP56 cell tumors 
was much slower than that of the PC-3/V cell tumors (Fig. 1E 
and 1F). These results are consistent with a number of findings 
that reported reduced hSP56 expression in cancers, supporting 
the conclusion that hSP56 suppresses the malignant character-
istics of prostate cancer cells.
hSP56 interacts with both VDU1 and VDU2
We then sought to understand mechanisms by which hSP56 
expression suppresses prostate cancer cell growth. We pre-
viously identified pVHL-interacting deubiquitinating enzyme 1 
(VDU1) as a protein interacting with hSP56 (14), thus extended 
this finding to examine whether hSP56 interacts also with hSP56 modulates the prostate cancer phenotype
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Fig. 2. hSP56 interacts with VDU1 and VDU2. (A) Expression of 
the full-length VDU1-HA and VDU2-HA in COS-7 cells. The in-
teraction of hSP56 with the full-length VDU1 and VDU2 was ex-
amined by ELISA-format in vitro binding (B) and co-immunopre-
cipitation (C). (D) Co-localization of hSP56 with VDU2. 4’,6-dia-
midino-2-phenylindole (DAPI) was used for nuclear staining. Scale 
bar, 10 μm. XF, transfection.
Fig. 3. hSP56 regulates HIF-1α protein levels. (A) PC-3 cells were 
transiently transfected with the indicated plasmids for 24 hr and 
plated into 6-well plates. After an additional 24 hr, the specified 
conditions were applied for 5 or 24 hr. (B) PC-3 cells prepared in 
6-well plates were transfected with increasing amounts of hSP56 
expression plasmid (equal to 1.5 μg total with vector) for 24 hr 
and treated with CoCl2 for 18 hr. Relative HIF-1α/β-actin levels 
quantified by the ImageJ software (NIH) are presented as % of that 
of vector transfected sample in panels A and B. Samples exhibiting 
significantly reduced HIF-1α levels are indicated in italicized, un-
derlined fonts. (C) Quantitative RT-PCR to determine HIF1A mRNA 
levels.  GAPDH  mRNA levels were used as normalization controls. 
(D) PC-3 cells stably transfected with hSP56 exhibited a reduction 
of HIF-1α protein level induced by the indicated CoCl2 treatment 
for 18 hr. Sections within an identical membrane were combined. 
(E) HIF-1α stabilization was not significantly affected by hSP56 
knock-down in LNCaP cells. Increasing concentrations of CoCl2 (0, 
12, 25, 50, 100 and 200 μM) were used for the experiment pre-
sented on the right panel. (F) LNCaP cells express much lower lev-
el of HIF1A mRNA compared to PC-3 cells. (G) HIF-1α stabiliza-
tion in LNCaP and PC-3 cells. The cells were treated as indicated 
for 18 hr, and the cell lysates were analyzed by immunoblotting 
with the indicated antibodies. LNCaP and PC-3 cell samples were 
blotted to separate membranes, but processed together under the 
same conditions. Two exposure times (7 sec and 60 sec) are 
shown for anti-HIF-1α immunoblotting to compare the HIF-1α sig-
nals in two cell samples. Note that MG132 robustly increased 
HIF-1α in PC-3 cells, but not in LNCaP cells.
VDU2, a closely related isoform of VDU1.  We incubated solu-
ble extracts of COS-7 cells mock transfected, or transfected 
with vector alone or with VDU1-HA or VDU2-HA in a 96-well 
plate coated with BSA or hSP56, and analyzed protein inter-
action by anti-HA ELISA. The expression levels of VDU1 and 
VDU2 from the transiently transfected COS-7 cells were similar 
(Fig. 2A). Interestingly, we observed a stronger interaction be-
tween VDU2 and hSP56 than between VDU1 and hSP56 (Fig. 
2B).  We investigated the interactions of hSP56 with VDU1 and 
VDU2 further by co-immunoprecipitation. Soluble extracts of 
LNCaP cells transfected with VDU1-HA or VDU2-HA were im-
munoprecipitated using anti-HA antibody or normal mouse 
IgG, and analyzed by anti-hSP56 immunoblotting. The mem-
brane was then stripped and reprobed with anti-HA-bio-
tin/streptavidin-HRP conjugates. hSP56 was co-immunopre-
cipitated specifically with either VDU1-HA or VDU2-HA using 
anti-HA antibody, but not using normal mouse IgG (Fig. 2C), 
confirming that hSP56 interacts with both VDU1 and VDU2. 
We also attempted co-immunoprecipitation experiments at 
their endogenous expression levels, however available anti-
bodies against VDU1 and VDU2 have failed to detect the pro-
teins specifically. Similar to our previous demonstration with 
hSP56 and VDU1 interactions (14), VDU2 (red fluorescence 
from anti-HA/anti-mouse IgG-Texas Red) and hSP56 (green flu-
orescence from hSP56-EGFP) overlapped in the cytoplasm (Fig. hSP56 modulates the prostate cancer phenotype
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2D). These results suggest that the interaction of hSP56 with 
VDU2 is relevant. 
hSP56 down-regulates HIF-1α protein
VDU2 stabilizes HIF-1α by its deubiquitinating activity, result-
ing in the increased expression of hypoxia responsive genes 
(18). Therefore, we examined the effect of hSP56 expression 
on HIF-1α stabilization. PC-3 cells were transfected with 
hSP56 expression plasmid or vector alone and then incubated 
under the specified conditions for 5 or 24 hr (Fig. 3A). 
Transient expression of hSP56 resulted in significantly reduced 
HIF-1α under hypoxic conditions (1% O2) as well as under si-
mulated hypoxic conditions (100 μM CoCl2 treatment). The 
extent of the HIF-1α protein reduction (to 38-57% relative to 
vector transfected cells) is remarkable, especially considering 
that the transfection efficiency was between 48-66% de-
termined by EGFP transfection under similar conditions 
(Supplementary Fig. S3). hSP56 expression reduced HIF-1α 
protein stabilized by CoCl2 treatment to 91% at 5 hr and to 
66% at 24 hr. The less efficient reduction of HIF-1α by hSP56 
expression observed at the early time point with CoCl2 may be 
due to the robust effect of CoCl2 treatment in stabilization of 
HIF-1α. These findings suggest that hSP56 may function at a 
point downstream of already stabilized HIF-1α, i.e., ubiquiti-
nation and protein degradation.
　We investigated the negative regulation of HIF-1α by hSP56 
further by transfecting PC-3 cells with increasing amounts of 
hSP56 expression plasmid (Fig. 3B). HIF-1α protein was down 
regulated up to 49% of vector transfected control, and the re-
duction correlated with hSP56 expression levels. This 
hSP56-mediated HIF-1α down regulation did not occur at the 
gene transcription level, since HIF1A mRNA expression, as 
measured by quantitative RT-PCR, was unchanged by vector 
or hSP56 transfection (Fig. 3C). The long-term effect of hSP56 
expression on HIF-1α stabilization also was determined using 
the stable cell lines. PC-3/hSP56 cells exhibited almost no sta-
bilization of HIF-1α in the presence of 100 μM CoCl2 (Fig. 
3D), consistent with the immediate early effect of hSP56 ex-
pression on HIF-1α (Fig. 3A and 3B). 
　In contrast, LNCaP/hSP56
KD cells did not exhibit an increase 
of HIF-1α protein with CoCl2 treatment (Fig. 3E). HIF-1α pro-
tein level in LNCaP cells appears to be regulated differentially 
from that in PC-3 cells. Firstly, HIF-1α mRNA expression is 
much lower in LNCaP cells than in PC-3 cells (Fig. 3F). 
Secondly, LNCaP cells responded quite distinctively to 
MG132, a potent proteasome inhibitor. MG132 inhibits the 
proteasome-mediated protein degradation pathways, con-
sequently preventing HIF-1α degradation (19). However, 
MG132 did not increase HIF-1α protein level in LNCaP cells, 
while PC-3 cells exhibited a robust stabilization of HIF-1α by 
MG132 (Fig. 3G). This finding suggests that the protea-
some-mediated protein degradation pathway may not be a ma-
jor regulatory mechanism for HIF-1α in LNCaP cells. These 
differences in HIF-1α regulation may be an explanation for the 
lack of the enhanced HIF-1α stabilization in LNCaP/hSP56
KD 
cells. Further investigation of the differential regulation of 
HIF-1α in these cells will provide important information re-
garding the regulation of hypoxic responses in prostate cancer 
cells.
　The function of hSP56 had been difficult to elucidate since 
its discovery (2, 20, 21). The expression of highly conserved 
homologs in both animal and plant kingdoms (22) implies a 
fundamental role for this protein in cell biology. In the present 
study, we have identified hSP56 as a basic regulator of the cell 
growth phenotype and as a negative regulator of HIF-1α stabi-
lization in prostate cancer cells. Notably, the mouse homolog 
of hSP56 has been identified as a novel target of HIF-1α (23). 
Our current findings, together with this observation, may sug-
gest a feedback regulation between HIF-1α and hSP56. The 
balance of HIF-1α and hSP56 that is well maintained in nor-
mal cellular physiology may be disturbed by yet unidentified 
mechanisms in human malignancies. 
　HIF-1α and hypoxia inducible genes, such as VEGF, play 
important roles in tumor progression (17). As noted earlier, re-
duced hSP56 expression has been observed in many types of 
human cancer. Also, decreased expression of hSP56 has been 
associated with a poor clinical outcome in several human can-
cers, including lung adenocarcinoma (4), pleural meso-
thelioma (24) and colorectal carcinomas (6, 7). These associa-
tions in several cancer types may be explained by loss of 
hSP56’s function in destabilization of HIF-1α. The expression 
of the gene encoding hSP56 (SELENBP1) in colon cancer was 
shown to be downregulated by hypermethylation in its pro-
moter region (25). It will be important to investigate whether 
this mechanism is operative in the reduction of hSP56 ex-
pression in multiple cancers. Demethylating agents that can re-
verse the reduced hSP56 expression, consequently recovering 
the normal balance of HIF-1α and hSP56, may become inter-
esting candidates for future chemopreventive drug develop-
ment. Understanding the mechanisms by which hSP56 ex-
pression is regulated may become useful to understand the 
functions of hSP56 in other diseases, since SELENBP1 gene ex-
pression has been shown to be upregulated in major psychotic 
disorders such as schizophrenia (26, 27).
　Our findings in prostate cancer cells perhaps can be ex-
trapolated into other types of cancer as well, an idea supported 
by data that we obtained by expressing hSP56 in a human 
lung carcinoma cell line, A549, where ectopic expression of 
hSP56 downregulated HIF-1α stabilization (Supplementary 
Fig. S4). In a hepatocellular carcinoma cell line (SMMC7721), 
however, downregulation of hSP56 rather decreased HIF-1α 
protein level (28). Different cell types may have distinct mech-
anisms maintaining the balance between hSP56 and HIF-1α. It 
will be further investigated whether the protein-protein inter-
actions of hSP56 with VDU 1 and/or 2 are essential for HIF-1α 
regulation, or whether the negative regulation of HIF-1α by 
hSP56 is essential for suppressing the malignant characteristics 
of cancer cells. Our findings suggest that hSP56 exhibits an an-hSP56 modulates the prostate cancer phenotype
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ti-cancer action by mechanisms including that involved in neg-
ative regulation of HIF-1α stabilization in prostate cancer cells. 
MATERIALS AND METHODS
Plasmid construction and in vitro binding experiments
Construction of hSP56 expression plasmids is presented in 
Supplementary Fig. S5. For down-regulation of hSP56 ex-
pression, an shRNA construct containing targeting sequence of 
5’-catcacccacactccctattt (Open Biosystems) was used. Plasmids 
expressing VDU1 and VDU2 with a C-terminal HA-tag 
(VDU1-HA and VDU2-HA) were constructed as shown in 
Supplementary Fig. S6. Recombinant (His)6-hSP56 expressed 
in  E. coli was purified using Ni-NTA agarose (Qiagen) and 
used in the ELISA-format in vitro binding experiment as de-
scribed previously (14).
Mammalian cell culture and transfection
COS-7, PC-3 and LNCaP cells (American Type Culture 
Collection) were maintained in RPMI-1640 medium (for 
COS-7, Mediatech) or DMEM/F-12 medium (for PC-3 and 
LNCaP, Mediatech) containing 10% FBS (HyClone) and 1× 
penicillin/streptomycin (Invitrogen) at 37
oC in a humidified at-
mosphere of 95% air and 5% CO2. Hypoxic conditions were 
established either in a humidified hypoxia chamber (StemCell 
Technologies) purged with controlled gas mixtures containing 
1% O2 or by 100 μM CoCl2 treatment for simulated hypoxic 
conditions (29). Soft agar colony-forming assays were per-
formed as described (30). FuGene6 (Roche) was used to trans-
fect cells according to the manufacturer’s instructions. Stable 
cell lines were established by growing antibiotic-resistant 
clones from single cell colonies. 
Immunological methods
Co-immunoprecipitation was performed using soluble cell ly-
sates prepared with CytoBuster (Novagen), containing protease 
inhibitor cocktail set III (CalBiochem). The lysates were rotated 
overnight at 4
oC with 2 μg of anti-HA antibody (Covance) or 
normal mouse IgG (Jackson ImmunoResearch Laboratory). A 
50 μl suspension (1 : 1) of Protein A/G-agarose beads (Pierce) 
was added and incubated by rotation at 4
oC for 2 h. The im-
munoprecipitates were pelleted by centrifugation and washed 
three times with the lysis buffer. Both the immunoprecipitates 
and total cell lysates were analyzed by anti-hSP56 and anti-HA 
immunoblotting. Immunoblotting and immunofluorescence 
analyses were described previously (14).
RNA isolation and quantitative RT-PCR
RNA isolation and cDNA synthesis were described previously 
(31). Quantitative real-time PCR (qRT-PCR) was performed us-
ing the ABI 7300 real-time PCR system (Applied Biosystems) 
with iTaq SYBR Green Supermix (Bio-Rad). qRT-PCR validated 
primer sets for HIF1A and GAPDH mRNA detection were pur-
chased from RealTime Primers. 
In vivo tumorigenicity
Male SCID-ICR mice (6-week-old) were purchased from 
Taconic and housed in AALAC accredited animal facility. All 
procedures were approved by the Beth Israel Deaconess 
Medical Center Institutional Animal Care and Use Committee. 
Mice were randomized into two groups (n=8 each group) and 
injected subcutaneously, in the dorsal flank, with PC-3/Vector 
or PC-3/hSP56 cells (5 × 10
6 cells/animal). Tumor size was 
measured using a Vernier caliper and tumor volume was cal-
culated using the standard formula, volume = length ×   
(width)
2 × 0.52.
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